Stock Price Prediction

PLX stock closed at $2.43 on January 31, 2025, with a 2.10% gain during regular trading hours. The bullish view stems from Protalix BioTherapeutics becoming debt-free after repaying its 7.50% senior secured convertible promissory notes, which strengthens its balance sheet and operational stability. This financial improvement could support further growth, making $2.50 a potential short-term target.

PLX stock is bearish due to weak Q2 2024 financial performance, with a net loss of $2.20 million and declining revenue to $13.30 million from $15.08 million year-over-year. Despite becoming debt-free, the company's operational stability is overshadowed by its inability to sustain profitability. The stock may face resistance near $2.50, with limited upside unless revenue growth improves.

The market consensus for PLX's revenue in the upcoming quarter is projected to be approximately $21.6M USD.